AUDUBON, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced its financial results for the third quarter ended September 30, 2018.

  • Worldwide sales were $169.2 million, an increase of 11.5% as reported
  • Third quarter net income was $35.2 million, an increase of 37.6%
  • Diluted earnings per share (EPS) was $0.35 and non-GAAP diluted EPS was $0.39
  • Non-GAAP diluted EPS increased 29.2% compared to third quarter of 2017
  • Non-GAAP adjusted EBITDA was 34.1% of sales

“The third quarter marks the fourth consecutive quarter of double-digit organic growth for Globus Medical, as our U.S. Spine business continues to take market share, growing by 7.5%; our international revenue increased by 16.8%; and Emerging Technologies contributed $6.3 million," said Dave Demski, CEO.  "During the third quarter, we completed the acquisition of Surgimap®, the leading surgical planning software for spine.  The addition of Surgimap® will further strengthen Globus Medical’s ExcelsiusGPS® platform by streamlining workflow and enabling superior data analytics.  The level of adoption we are seeing by surgeons in accounts with our ExcelsiusGPS® robotic system continues to show positive momentum and the pipeline for potential robotic sales is robust."

Worldwide sales for the third quarter were $169.2 million, an increase of 11.5% over the third quarter of 2017.  Revenue from Emerging Technologies was primarily due to continued demand for our ExcelsiusGPS® robotics and navigation system.

Third quarter sales in the U.S., including robotics, increased by 10.5% compared to the third quarter of 2017.  International sales increased by 16.8% over the third quarter of 2017 on an as-reported basis and 18.5% on a constant currency basis.

Third quarter GAAP net income was $35.2 million, an increase of 37.6% over the same period last year.  Diluted EPS for the third quarter was $0.35, as compared to $0.26 for the third quarter 2017.  Non-GAAP diluted EPS for the third quarter was $0.39, compared to $0.30 in the third quarter of 2017, an increase of 29.2%.

The company generated net cash provided by operating activities of $51.8 million and non-GAAP free cash flow of $36.4 million in the third quarter, and ended the quarter with cash, cash equivalents and marketable securities of $541.6 million.  The company remains debt free.

2018 Annual Guidance
The company today issued new guidance for full year 2018 sales of $705 million and non-GAAP diluted earnings per share of $1.62.  2018 guidance was previously sales of $700 million and non-GAAP diluted earnings per share of $1.55.

Conference Call Information
Globus Medical will hold a teleconference to discuss its 2018 third quarter results with the investment community at 4:30 p.m. Eastern Time today.  Globus invites all interested parties to join the call by dialing:

  
1-855-533-7141United States Participants
1-720-545-0060 International Participants
There is no pass code for the teleconference.
  

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at investors.globusmedical.com.

The call will be archived until Thursday, November 15, 2018.  The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 1012-6377.

About Globus Medical, Inc.
Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures.  For example, non-GAAP adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, provisions for litigation, and acquisition related costs/licensing, and net gain from the sale of assets, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense.  Our management also uses non-GAAP adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections.  Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized.  Acquisition related costs/licensing represents the change in fair value of business acquisition related contingent consideration; costs related to integrating recently acquired businesses including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees, as well as one-time licensing fees.   Net gain from sale of assets represents the gain on sale of assets and the offsetting impact of costs incurred through the sale.

In addition, for the period ended September 30, 2018 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted earnings per share, which represents net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition related costs/licensing, net gain from the sale of assets and the tax effects of such adjustments.  We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, amortization of intangibles, acquisition related costs/licensing, net gain from the sale of assets and the tax effects of such adjustments, which we believe are not reflective of underlying business trends.  Additionally, for the periods ended September 30, 2018 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment.  We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions.  Furthermore, the non-GAAP measure of constant currency sales growth is calculated by translating current year sales at the same average exchange rates in effect during the applicable prior year period.  We believe constant currency sales growth provides insight to the comparative increase or decrease in period sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth are not calculated in conformity with U.S. GAAP.  Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP.  These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results.  Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency sales growth may differ from that of other companies and therefore may not be comparable.  Additionally, we have recast prior periods for non-GAAP net income and non-GAAP diluted earnings per share.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms.  These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends.  Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted.  These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to successfully integrate the international operations acquired from Alphatec, both in general and on our anticipated timeline, our ability to transition Alphatec’s international customers to Globus products, our ability to realize the expected benefits to our results from the Alphatec acquisition, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks.  For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission.  These documents are available at www.sec.gov.  Moreover, we operate in an evolving environment.  New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.  Forward-looking statements contained in this press release speak only as of the date of this press release.  We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

 
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
 
 Three Months Ended Nine Months Ended
(In thousands, except per share amounts)September 30,
 2018
 September 30,
 2017
 September 30,
 2018
 September 30,
 2017
Sales$169,236  $151,744  $517,031  $459,943 
Cost of goods sold37,849  36,798  113,456  109,597 
Gross profit131,387  114,946  403,575  350,346 
        
Operating expenses:       
Research and development15,527  10,887  41,738  32,266 
Selling, general and administrative75,131  63,362  227,949  194,859 
Provision for litigation  2,537    2,780 
Amortization of intangibles2,160  2,080  6,525  5,671 
Acquisition related costs268  285  1,289  1,290 
Total operating expenses93,086  79,151  277,501  236,866 
        
Operating income38,301  35,795  126,074  113,480 
Other income/(expense), net4,296  1,562  14,904  5,848 
Income before income taxes42,597  37,357  140,978  119,328 
Income tax provision7,389  11,766  21,254  36,356 
        
Net income$35,208  $25,591  $119,724  $82,972 
        
Earnings per share:       
Basic$0.36  $0.27  $1.23  $0.86 
Diluted$0.35  $0.26  $1.18  $0.85 
Weighted average shares outstanding:       
Basic98,328  96,318  97,671  96,160 
Diluted101,804  97,849  101,275  97,607 
            


 
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
 
(In thousands, except par value)September 30,
 2018
 December 31,
 2017
    
ASSETS(unaudited)  
Current assets:   
Cash and cash equivalents$145,295  $118,817 
Short-term marketable securities227,466  254,890 
Accounts receivable, net of allowances of $3,655 and $3,963, respectively118,847  116,676 
Inventories124,372  108,409 
Prepaid expenses and other current assets13,951  11,166 
Current portion of note receivable3,333  1,667 
Income taxes receivable13,137  8,717 
Total current assets646,401  620,342 
Property and equipment, net of accumulated depreciation of $210,120 and $191,760, respectively161,768  143,167 
Long-term marketable securities168,850  56,133 
Note receivable25,833  28,333 
Intangible assets, net89,522  78,659 
Goodwill124,015  123,890 
Other assets6,726  7,947 
Deferred income taxes15,391  20,031 
Total assets$1,238,506  $1,078,502 
    
LIABILITIES AND EQUITY   
Current liabilities:   
Accounts payable$23,061  $25,039 
Accrued expenses47,764  52,594 
Income taxes payable2,322  3,274 
Business acquisition liabilities6,693  11,411 
Deferred revenue1,878  755 
Total current liabilities81,718  93,073 
Business acquisition liabilities, net of current portion3,378  4,508 
Deferred income taxes9,623  10,669 
Other liabilities2,670  2,474 
Total liabilities97,389  110,724 
Commitments and contingencies   
Equity:   
Common stock; $0.001 par value.  Authorized 785,000 shares; issued and outstanding 98,450 and 96,658 shares at September 30, 2018 and December 31, 2017, respectively99  97 
Additional paid-in capital291,875  238,341 
Accumulated other comprehensive loss(6,828) (6,907)
Retained earnings855,971  736,247 
Total equity1,141,117  967,778 
Total liabilities and equity$1,238,506  $1,078,502 
        



 
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
 Nine Months Ended
(In thousands)September 30,
 2018
 September 30,
 2017
Cash flows from operating activities:   
Net income$119,724  $82,972 
Adjustments to reconcile net income to net cash provided by operating activities:   
Depreciation and amortization29,694  33,773 
Amortization of premium on marketable securities1,808  2,258 
Write-down for excess and obsolete inventories8,326  8,158 
Stock-based compensation expense17,078  10,659 
Allowance for doubtful accounts388  1,135 
Change in fair value of business acquisition liabilities592  1,011 
Change in deferred income taxes1,606  815 
(Gain)/loss on disposal of assets, net(3,694)  
(Increase)/decrease in:   
Accounts receivable(2,900) (2,200)
Inventories(23,042) (6,956)
Prepaid expenses and other assets(81) (974)
Increase/(decrease) in:   
Accounts payable(4,858) (344)
Accrued expenses and other liabilities(1,965) (9,377)
Income taxes payable/receivable(5,324) (6,709)
Net cash provided by operating activities137,352  114,221 
    
Cash flows from investing activities:   
Purchases of marketable securities(382,347) (227,699)
Maturities of marketable securities210,066  168,418 
Sales of marketable securities85,234  34,751 
Purchases of property and equipment(42,538) (37,878)
Proceeds from sale of assets4,000   
Acquisition of businesses, net of cash acquired, and purchases of intangible and other assets(14,825) (31,501)
Net cash used in investing activities(140,410) (93,909)
    
Cash flows from financing activities:   
Payment of business acquisition liabilities(6,513) (5,234)
Proceeds from exercise of stock options36,245  6,943 
Net cash (used in)/provided by financing activities29,732  1,709 
    
Effect of foreign exchange rate on cash(196) 778 
    
Net increase in cash, cash equivalents, and restricted cash26,478  22,799 
Cash, cash equivalents, and restricted cash, beginning of period118,817  67,431 
Cash, cash equivalents, and restricted cash, end of period$145,295  $90,230 
    
Supplemental disclosures of cash flow information:   
Interest paid  34 
Income taxes paid$24,894  $49,008 
        



 
Supplemental Financial Information
 
Sales by Geographic Area:
 
(Unaudited)Three Months Ended Nine Months Ended
(In thousands)September 30,
 2018
 September 30,
 2017
 September 30,
 2018
 September 30,
 2017
United States$139,097  $125,933  $429,823  $381,870 
International30,139  25,811  87,208  78,073 
Total sales$169,236  $151,744  $517,031  $459,943 
                


 
Sales by Revenue Stream:
 
(Unaudited)Three Months Ended Nine Months Ended
(In thousands)September 30,
 2018
 September 30,
 2017
 September 30,
 2018
 September 30,
 2017
Spine products$162,952  $151,744  $484,149  $459,943 
Emerging Technology products6,284    32,882   
Total sales$169,236  $151,744  $517,031  $459,943 
                


 
Liquidity and Capital Resources:
    
(Unaudited)September 30,
 2018
 December 31,
 2017
(In thousands)   
Cash and cash equivalents$145,295  $118,817 
Short-term marketable securities227,466  254,890 
Long-term marketable securities168,850  56,133 
Total cash, cash equivalents and marketable securities$541,611  $429,840 
        

The following tables reconcile GAAP to Non-GAAP financial measures.


 
Non-GAAP Adjusted EBITDA Reconciliation Table:
 
(Unaudited)Three Months Ended Nine Months Ended
(In thousands, except percentages)September 30,
 2018
 September 30,
 2017
 September 30,
 2018
 September 30,
 2017
Net income$35,208  $25,591  $119,724  $82,972 
Interest income, net(3,852) (1,738) (9,114) (4,746)
Provision for income taxes7,389  11,766  21,254  36,356 
Depreciation and amortization10,461  10,838  29,694  33,773 
EBITDA49,206  46,457  161,558  148,355 
Stock-based compensation expense5,545  3,596  17,078  10,659 
Provision for litigation  2,537    2,780 
Acquisition related costs/licensing2,169  784  3,847  2,838 
Net gain from sale of assets764    (3,593)  
Adjusted EBITDA$57,684  $53,374  $178,890  $164,632 
        
Net income as a percentage of sales20.8% 16.9% 23.2% 18.0%
Adjusted EBITDA as a percentage of sales34.1% 35.2% 34.6% 35.8%
            


 
Non-GAAP Net Income Reconciliation Table:
 
(Unaudited)Three Months Ended Nine Months Ended
(In thousands)September 30,
 2018
 September 30,
 2017
 September 30,
 2018
 September 30,
 2017
Net income$35,208  $25,591  $119,724  $82,972 
Provision for litigation  2,537    2,780 
Amortization of intangibles2,160  2,080  6,525  5,671 
Acquisition related costs/licensing2,169  784  3,847  2,838 
Net gain from sale of assets764    (3,593)  
Tax effect of adjusting items(884) (1,677) (1,248) (3,443)
Non-GAAP net income$39,417  $29,315  $125,255  $90,818 
                


 
Non-GAAP Diluted Earnings Per Share Reconciliation Table:
 
(Unaudited)Three Months Ended Nine Months Ended
(Per share amounts)September 30,
 2018
 September 30,
 2017
 September 30,
 2018
 September 30,
 2017
Diluted earnings per share, as reported$0.35  $0.26  $1.18  $0.85 
Provision for litigation  0.03    0.03 
Amortization of intangibles0.02  0.02  0.06  0.06 
Acquisition related costs/licensing0.02  0.01  0.04  0.03 
Net gain from sale of assets0.01    (0.04)  
Tax effect of adjusting items(0.01) (0.02) (0.01) (0.04)
Non-GAAP diluted earnings per share$0.39  $0.30  $1.24  $0.93 
* amounts might not add due to rounding       


 
Non-GAAP Free Cash Flow Reconciliation Table:
 
(Unaudited)Three Months Ended Nine Months Ended
(In thousands)September 30,
 2018
 September 30,
 2017
 September 30,
 2018
 September 30,
 2017
Net cash provided by operating activities$51,788  $34,795  $137,352  $114,221 
Adjustment for impact of restricted cash       
Purchases of property and equipment(15,371) (12,817) (42,538) (37,878)
Non-GAAP free cash flow$36,417  $21,978  $94,814  $76,343 
                


 

                  
(Unaudited)Three Months Ended Reported Growth Currency
Impact on
Current Period
 Constant
Currency
Growth
(In thousands, except percentages)September 30, September 30,   
20182017
United States$139,097  $125,933  10.5%   10.5%
International30,139  25,811  16.8% $(436) 18.5%
Total sales$169,236  $151,744  11.5% $(436) 11.8%
  
  
(Unaudited)Nine Months Ended Reported Growth Currency
Impact on
Current Period
 Constant
Currency
Growth
(In thousands, except percentages)September 30, September 30,   
20182017
United States$429,823  $381,870  12.6%   12.6%
International87,208  78,073  11.7% $2,061  9.1%
Total sales$517,031  $459,943  12.4% $2,061  12%
 
 


Contact
:
Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com